Originally published as JCO Early Release 10.1200/JCO.2005.04.057 on November 22 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shah, N. T. Articles by Miller, V. A. Search for Related Content PubMed PubMed Citation Articles by Shah, N. T. Articles by Miller, V. A. Social Bookmarking                            What's this?

Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib

From the Thoracic Oncology Service, Division of Solid Tumor Oncology, and Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center; and Departments of Biostatistics, Surgery, and Radiology, Weill Medical College of Cornell University, New York, NY

Address reprint requests to Mark G. Kris, MD, Memorial Hospital, 1275 York Avenue, New York, NY 10021; e-mail: krism{at}mskcc.org

PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non–small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non–small-cell lung cancer.

METHODS: This article reviews gefitinib’s indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response.

RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent.

CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K.-P. Xu, Y. Li, A. V. Ljubimov, and F.-S. X. Yu High Glucose Suppresses Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/Akt Signaling Pathway and Attenuates Corneal Epithelial Wound Healing Diabetes, May 1, 2009; 58(5): 1077 - 1085. [Abstract] [Full Text] [PDF]

				A. Nogueira-Rodrigues, C. C. do Carmo, C. Viegas, F. Erlich, C. Camisao, K. Fontao, R. Lima, D. Herchenhorn, R. G. Martins, G. M. Moralez, et al. Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6324 - 6329. [Abstract] [Full Text] [PDF]

				F. Braiteh, R. Kurzrock, and F. M. Johnson Trichomegaly of the Eyelashes After Lung Cancer Treatment with the Epidermal Growth Factor Receptor Inhibitor Erlotinib J. Clin. Oncol., July 10, 2008; 26(20): 3460 - 3462. [Full Text] [PDF]

				R. Lilenbaum, R. Axelrod, S. Thomas, A. Dowlati, L. Seigel, D. Albert, K. Witt, and D. Botkin Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2 J. Clin. Oncol., February 20, 2008; 26(6): 863 - 869. [Abstract] [Full Text] [PDF]

				B. Moy and P. E. Goss Lapatinib-Associated Toxicity and Practical Management Recommendations Oncologist, July 1, 2007; 12(7): 756 - 765. [Abstract] [Full Text] [PDF]

				P Specenier, C Koppen, and J. Vermorken Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy Ann. Onc., May 1, 2007; 18(5): 961 - 962. [Full Text] [PDF]

				J Lee, W. Kang, J. Kwon, S. Oh, H. Lee, H. Kim, B. Park, H. Lim, M. Han, J. Park, et al. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma Ann. Onc., January 1, 2007; 18(1): 88 - 92. [Abstract] [Full Text] [PDF]

				D. B. Costa and M. S. Huberman Improvement of Type 2 Diabetes in a Lung Cancer Patient Treated With Erlotinib Diabetes Care, July 1, 2006; 29(7): 1711 - 1711. [Full Text] [PDF]

				Y.-M. Chen, J.-F. Shih, R.-P. Perng, C.-M. Tsai, and J. Whang-Peng A Randomized Trial of Different Docetaxel Schedules in Non-small Cell Lung Cancer Patients Who Failed Previous Platinum-Based Chemotherapy. Chest, April 1, 2006; 129(4): 1031 - 1038. [Abstract] [Full Text] [PDF]

				M. H Nelson and C. R Dolder Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors Ann. Pharmacother., February 1, 2006; 40(2): 261 - 269. [Abstract] [Full Text] [PDF]

				K. A. Tammaro, P. D. Baldwin, and A. S. Lundberg Interstitial lung disease following erlotinib (Tarceva(R)) in a patient who previously tolerated gefitinib (Iressa(R)) Journal of Oncology Pharmacy Practice, September 1, 2005; 11(3): 127 - 130. [Abstract] [PDF]

				S. Segaert and E. Van Cutsem Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann. Onc., September 1, 2005; 16(9): 1425 - 1433. [Abstract] [Full Text] [PDF]

				G. Giaccone Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-Small-Cell Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3235 - 3242. [Abstract] [Full Text] [PDF]

				M. K. Mohamed, S. Ramalingam, Y. Lin, W. Gooding, and C. P. Belani Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer Ann. Onc., May 1, 2005; 16(5): 780 - 785. [Abstract] [Full Text] [PDF]